Prana Biotechnology Limited (ADR) (NASDAQ:PRAN)
| CAPS Rating |
|
|---|
PRAN
VS S&P 500 (SPY)
PRAN News and Commentary
- Prana Biotechnology Receives FDA Approval to Commence Clinical Trial for Huntington's Disease Drug; – NASDAQ
- Closing Bell: Growth & Rebuilding Back On Track (BAC, CREE, MU, NFLX, PRAN) – BloggingStocks
- Stocks Lower at Mid-Day as Investors Weigh Geopolitical Events, Housing Data – NASDAQ
- Mid-Day Update: Stocks Modestly Lower as New Home Sales Hit Record Low – NASDAQ
- Closing Bell: Bulls Take a Breather (DG, EE, EWJ, NFLX, PRAN, S, T) – BloggingStocks
- Stocks Flat to Lower; Investors Consolidate Gains, Watch Events in Japan and Libya – NASDAQ
- Mid-Day Update: Stocks Near Flat as Investors Pause Following Yesterday's Surge – NASDAQ
- China Analyst: 10 Pharma Stocks With Highest Growth Potential – SeekingAlpha
This ticker is not currently Ratable.
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
Powered by: CAPSAll Players
25
Outperform
3
Underperform
All-Star Players
5
Outperform
0
Underperform
Wall Street
1
Outperform
0
Underperform
RSS Headlines
Fool UK
